Insys Therapeutics (NASDAQ: INSY) reported Q2 EPS of $0.06, $0.01 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $67.1 million versus the consensus estimate of $66.9 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.